| Autor: |
Howaida Abdelhameed Elshinnawy, Tamer Wahid El-Said, Sarah Farid Fahmy, Ahmed Shamseldin, Sherin Ibrahim, Reem Mohsen Elsharabasy |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
The Egyptian Journal of Internal Medicine, Vol 35, Iss 1, Pp 1-7 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2090-9098 |
| DOI: |
10.1186/s43162-022-00181-1 |
| Popis: |
Abstract Background and aim Vascular calcification is a significant risk factor for cardiovascular diseases in patients with end-stage renal disease, particularly those on hemodialysis. Previous research on vitamin K found that it had a positive on calcification markers. However, clinical data is still limited. This study aimed to compare the efficacy and safety of vitamin K2 versus vitamin k1 on a calcification regulator in hemodialysis patients. Methods A prospective randomized placebo-controlled trial was conducted on 120 patients, who were divided into three groups; group 1: administered 10 mg of vitamin K1 (phytomenadione thrice weekly); group 2: administered 90 μg of vitamin k2 (MK-7); group 3: administered placebo for 3 months. Matrix Gla protein (MGP), calcium, phosphorous, and intact parathyroid hormone levels were measured. Results MK-7 significantly increased active MGP levels compared to phytomenadione and placebo groups (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink